Skip to main contentSkip to navigationSkip to search


Kinnevik Stake
Biotechnology company tackling drug discovery through a nature-based approach

The market

The biotechnology and pharmaceutical markets are quickly evolving, fueled by a shift towards personalized medicine and targeted therapies. This transformation reflects an increasing demand for inventive drug discovery methods, paving the way for computational biology and data science to play a key role in offering efficient solutions to drug discovery challenges. 

While the traditional model of drug discovery has been struggling with rising R&D costs, lengthy development timelines, and a high attrition rate of drug candidates, there is now a greater emphasis than ever on leveraging computational biology, artificial intelligence, and big data analytics to overcome these hurdles and usher in a new generation of the drug discovery process. One where researchers can sift through vast amounts of data, identify potential drug candidates more efficiently, and predict their efficacy and safety profiles with greater accuracy. 

The company

Enveda is a biotechnology company at the forefront of using computational biology and data science to pioneer groundbreaking therapeutics. Founded in 2016 by Viswa Colluru, a PhD in molecular biology, Enveda is driven by the mission to unlock nature's vast chemical diversity to confront pressing medical challenges. 

While nature has long inspired drug discovery, its full potential has been limited by complexities in understanding its chemical makeup. Enveda aims to overcome these barriers by deploying innovative machine learning techniques, including large language models, to develop a comprehensive 'search engine' for cataloging and analyzing the chemical components of plants.

Enveda merges cutting-edge computational techniques with traditional medicinal chemistry and pharmacology to pinpoint potential drug candidates from natural sources such as plants, fungi, and microorganisms. Their proprietary platform then integrates machine learning algorithms, big data analytics, and high-throughput screening technologies to enable swift identification and analysis of extensive natural compound libraries. 

This innovative approach empowers Enveda to accelerate drug discovery, outpacing traditional methods. Focused on therapeutic areas with significant unmet medical needs—oncology, infectious diseases, and autoimmune disorders—Enveda collaborates strategically with pharmaceutical firms and research institutions to expedite the introduction of novel treatments worldwide.

The Investment Case

Investing in Enveda presents a compelling opportunity for several reasons. Firstly, the company's cutting-edge technology platform is revolutionizing drug discovery, offering a competitive advantage in identifying and developing novel therapeutics. By pioneering a dual strategy of advancing potential drugs to critical stages before determining whether to pursue in-house development or licensing to pharmaceutical partners, their strategic approach also manages to optimize market presence while mitigating R&D risks, capitalizing on their unique platform and position. 

Secondly, their focus on natural product-based drug discovery aligns perfectly with the increasing demand for innovative treatments derived from nature's chemical diversity. Furthermore, the company's strategic partnerships with industry leaders and research institutions provide invaluable resources and expertise, expediting drug development efforts. 

Despite being in its early stages, Enveda’s potential in transforming healthcare and drug discovery is highly promising. Overall, its innovative approach, strong partnerships, and the team’s dedication to addressing unmet medical needs translate well into our convictions and point of view of where the biotechnology sector is heading next, and we are thrilled to support the company on its journey.

Other investments